TACC3

Overview

TACC3 is a centrosomal/spindle protein best known in cancer genomics as the canonical 3’ fusion partner of FGFR3, producing oncogenic FGFR3-TACC3 fusions.

Alterations observed in the corpus

  • FGFR3-TACC3 fusions were observed among oncogenic FGFR3 alterations in urothelial carcinoma; FGFR3-fusion tumors had lower TMB than FGFR3-mutant tumors (median 5 vs 9 mut/Mb, p=0.0006) PMID:37682528.
  • TACC3 fusion partner with FGFR3 (4% of evaluable metastatic UC samples in UC-GENOME cohort) PMID:36333289
  • Noted as a background-context fusion partner: FGFR3:TACC3 fusions in adult glioblastoma are cited as the conceptual analog for the FGFR1 kinase-domain activations and FGFR1:TACC1 fusions identified in pediatric pilocytic astrocytoma PMID:23817572
  • FGFR3-TACC3 in-frame inversion fusion detected in 2 GBM cases with focal co-amplification; FGFR3/TACC3 focal amplification present in 2.6% of CNA profiles in the TCGA GBM cohort PMID:24120142
  • TACC3 is a partner in the FGFR3-TACC3 in-frame fusion (2/42 = 5% by RNA-seq) in TCC bladder cancer; encodes a microtubule-associated SCCS protein with outlier high expression driven by the FGFR3 promoter rather than amplification PMID:24121792
  • Recurrent in-frame FGFR3-TACC3 fusions (n=3) in bladder urothelial carcinoma (BLCA); TACC3 acts as the 3’ partner in this kinase fusion associated with FGFR3-driven oncogenesis PMID:24476821
  • Partner gene in recurrent FGFR3-TACC3 intrachromosomal fusions in 5 high-grade UTUC tumours (confirmed by Sanger sequencing); breakpoints in TACC3 intron 10 or exon 7; fusions predicted to produce constitutively active FGFR3-TACC3 chimeric protein PMID:26278805
  • FGFR3-TACC3 fusion identified in 1 patient in a prospective MSK-IMPACT cohort of 860 metastatic LUAD patients PMID:28336552.
  • FGFR3-TACC3 fusion identified in 1 low-grade Ta NMIBC tumor; novel fusion detected by targeted NGS panel in the MSK NMIBC cohort (n=105) PMID:28583311
  • FGFR3-TACC3 fusion first reported in cholangiocarcinoma; previously characterized as oncogenic in bladder cancer, glioblastoma, and lung cancer PMID:28667006
  • Fusion partner of FGFR3 in the recurrent intra-chromosomal FGFR3-TACC3 fusion (n=10), an in-frame activating event particularly enriched in the luminal-papillary MIBC subtype PMID:28988769
  • FGFR3-TACC3 is a recurrent inframe activating kinase fusion across BLCA (2.0%), CESC (1.7%), and LUSC (1.2%); FGFR3 named as a druggable target in 15 cancer types in the TCGA pan-cancer fusion landscape PMID:29617662

Cancer types (linked)

  • BLCA / UTUC — FGFR3-TACC3 fusions contribute to the actionable FGFR3-altered population PMID:37682528.

Co-occurrence and mutual exclusivity

Therapeutic relevance

Open questions

  • Whether FGFR3-fusion tumors respond differently to erdafitinib than FGFR3-mutant tumors is not directly resolved in the corpus PMID:37682528.

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:36333289

This page was processed by crosslinker on 2026-05-14. - PMID:23817572

This page was processed by crosslinker on 2026-05-14. - PMID:24120142

This page was processed by crosslinker on 2026-05-14. - PMID:24121792

This page was processed by crosslinker on 2026-05-14. - PMID:24476821

This page was processed by crosslinker on 2026-05-14. - PMID:26278805

This page was processed by crosslinker on 2026-05-14. - PMID:28336552

This page was processed by wiki-cli on 2026-05-14. - PMID:28583311

This page was processed by wiki-cli on 2026-05-15. - PMID:28667006

This page was processed by wiki-cli on 2026-05-15. - PMID:28988769

This page was processed by wiki-cli on 2026-05-15. - PMID:29617662

This page was processed by wiki-cli on 2026-05-15.